Ocriplasmin for Vitromacular Adhesion is filed at EMA

The European Medicines Agency has accepted for review ocriplasmin (2.5 mg/ml, solution for injection) from Thrombogenics ,for the treatment of symptomatic Vitreomacular Adhesion (VMA) including macular hole. Ocriplasmin's MAA will be evaluated through the EMA's centralised procedure with an official start date of 19 October 2011 and, if approved, the product will gain marketing authorisation for all EU Member States simultaneously. Successful approval will make it the first pharmacological treatment for this indication. The company has kept to its stated time frames for the European filing and in announcing the EMA's acceptance of the MAA, the company once more reiterated its plans for the treatment to be filed with the US FDA by the end of the year